datamatters24/research-document-archive huggingface dataset:
I 
109TH CONGRESS 
1ST SESSION H. R. 1880 
To suspend temporarily the duty on 2,4-Dichloroaniline. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 27, 2005 
Mr. CLEAVER introduced the following bill; which was referred to the 
Committee on Ways and Means 
A BILL 
To suspend temporarily the duty on 2,4-Dichloroaniline. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. 2,4-DICHLOROANILINE. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.05.74 
2,4-Dichloroaniline (CAS 
No. 554–00–7) (provided for 
in subheading 2921.42.18) ..
Free 
No change 
No change 
On or before 
12/31/2008 
’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from
warehouse for consumption, on or after the 15th day after 
the date of enactment of this Act. 
Æ
SEC. 117. CONTINUITY OF CARE. 
(a) TERMINATION OF PROVIDER.— 
(1) IN GENERAL.—If— 
(A) a contract between a group health 
plan, or a health insurance issuer offering 
health insurance coverage, and a treating health 
care provider is terminated (as defined in para-
graph (e)(4)), or 
(B) benefits or coverage provided by a 
health care provider are terminated because of 
a change in the terms of provider participation 
in such plan or coverage, 
the plan or issuer shall meet the requirements of 
paragraph (3) with respect to each continuing care 
patient. 
(2) TREATMENT
OF
TERMINATION
OF
CON-
TRACT
WITH
HEALTH
INSURANCE
ISSUER.—If a 
contract for the provision of health insurance cov-
erage between a group health plan and a health in-
surance issuer is terminated and, as a result of such 
termination, coverage of services of a health care 
provider is terminated with respect to an individual, 
the provisions of paragraph (1) (and the succeeding 
provisions of this section) shall apply under the plan 
in the same manner as if there had been a contract 
between the plan and the provider that had been ter-
minated, but only with respect to benefits that are 
covered under the plan after the contract termi-
nation. 
(3) REQUIREMENTS.—The requirements of this 
paragraph are that the plan or issuer— 
(A) notify the continuing care patient in-
volved, or arrange to have the patient notified 
pursuant to subsection (d)(2), on a timely basis 
of the termination described in paragraph (1) 
(or paragraph (2), if applicable) and the right 
to elect continued transitional care from the 
provider under this section; 
(B) provide the patient with an oppor-
tunity to notify the plan or issuer of the pa-
tient’s need for transitional care; and 
(C) subject to subsection (c), permit the 
patient to elect to continue to be covered with 
respect to the course of treatment by such pro-
vider with the provider’s consent during a tran-
sitional period (as provided for under subsection 
(b)). 
(4) CONTINUING CARE PATIENT.—For purposes 
of this section, the term ‘‘continuing care patient’’ 
means a participant, beneficiary, or enrollee who—
I 
109TH CONGRESS 
1ST SESSION H. R. 1881 
To suspend temporarily the duty on 2-Acetylbutyrolactone. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 27, 2005 
Mr. CLEAVER introduced the following bill; which was referred to the 
Committee on Ways and Means 
A BILL 
To suspend temporarily the duty on 2-Acetylbutyrolactone. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. 2-ACETYLBUTYROLACTONE. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.05.75 
2-Acetylbutyrolactone (CAS 
No. 517–23–7) (provided for 
in subheading 2932.29.50) ..
Free 
No change 
No change 
On or before 
12/31/2008 
’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from
warehouse for consumption, on or after the 15th day after 
the date of enactment of this Act. 
Æ
I 
109TH CONGRESS 
1ST SESSION H. R. 2139 
To suspend temporarily the duty on Methyl 2-[(4,6-dimethoxypyrimidin-2- 
ylcarbamoyl)sulfamoyl]-G6a-(met hanesulfonamido)-p-toluate whether or 
not mixed with application adjuvants. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 5, 2005 
Mr. BERRY introduced the following bill; which was referred to the Committee 
on Ways and Means 
A BILL 
To suspend temporarily the duty on Methyl 2-[(4,6- 
dimethoxypyrimidin-2-ylcarbamoyl)sulfamoyl]-G6a-(met 
hanesulfonamido)-p-toluate whether or not mixed with 
application adjuvants. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
SECTION 
1. 
METHYL 
2-[(4,6-DIMETHOXYPYRIMIDIN-2- 
YLCARBAMOYL)SULFAMOYL]-α- 
(METHANESULFONAMIDO)-p-TOLUATE 
WHETHER OR NOT MIXED WITH APPLICA-
TION ADJUVANTS. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.06.76 
Methyl 2-[(4,6- 
dimethoxypyrimidin-2- 
ylcarbamoyl)sulfamoyl]-α- 
(methanesulfonamido)-p- 
toluate (CAS No. 208465– 
21–8) whether or not mixed 
with application adjuvants 
(provided for in subheading 
2935.00.75 or 3808.30.15) ..
Free 
No change 
No change 
On or before 
12/31/2008 
’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from 
warehouse for consumption, on or after the 15th day after 
the date of the enactment of this Act. 
Æ
(A) is undergoing a course of treatment 
for a serious and complex condition from the 
provider at the time the plan or issuer receives 
or provides notice of provider, benefit, or cov-
erage termination described in paragraph (1) 
(or paragraph (2), if applicable); 
(B) is undergoing a course of institutional 
or inpatient care from the provider at the time 
of such notice; 
(C) is scheduled to undergo non-elective 
surgery from the provider at the time of such 
notice; 
(D) is pregnant and undergoing a course 
of treatment for the pregnancy from the pro-
vider at the time of such notice; or 
(E) is or was determined to be terminally 
ill (as determined under section 1861(dd)(3)(A) 
of the Social Security Act) at the time of such 
notice, but only with respect to a provider that 
was treating the terminal illness before the date 
of such notice. 
(b) TRANSITIONAL PERIODS.— 
(1) SERIOUS AND COMPLEX CONDITIONS.—The 
transitional period under this subsection with re-
spect to a continuing care patient described in sub-
I 
109TH CONGRESS 
1ST SESSION H. R. 1882 
To suspend temporarily the duty on Alkylketone. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 27, 2005 
Mr. CLEAVER introduced the following bill; which was referred to the 
Committee on Ways and Means 
A BILL 
To suspend temporarily the duty on Alkylketone. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. ALKYLKETONE. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.05.76 
1-(4-chlorophenyl)–4, 4-di-
methyl-3-pentanone (CAS 
No. 66346–01–8) (provided 
for in subheading 
2914.70.40) .........................
Free 
No change 
No change 
On or before 
12/31/2008 
’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from
warehouse for consumption, on or after the 15th day after 
the date of enactment of this Act. 
Æ
I 
109TH CONGRESS 
1ST SESSION 
H. R. 213
To amend the Safe Drinking Water Act to require a national primary drinking 
water regulation for perchlorate. 
IN THE HOUSE OF REPRESENTATIVES 
JANUARY 4, 2005
Ms. SOLIS (for herself, Mr. DINGELL, Mrs. CAPPS, and Mr. STUPAK) intro-
duced the following bill; which was referred to the Committee on Energy 
and Commerce 
A BILL 
To amend the Safe Drinking Water Act to require a national 
primary drinking water regulation for perchlorate.
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. SHORT TITLE. 
This Act may be cited as the ‘‘Safe Drinking Water 
for Healthy Communities Act of 2005’’. 
SEC. 2. NATIONAL PRIMARY DRINKING WATER REGULA-
TION FOR PERCHLORATE. 
Section 1412(b)(12) of the Safe Drinking Water Act 
(42 U.S.C. 300g–1(b)(12)) is amended by adding at the 
end the following:
‘‘(C) PERCHLORATE.—
‘‘(i) SCHEDULE
AND
STANDARD.—
Notwithstanding the deadlines set forth in 
paragraph (1), the Administrator shall 
promulgate a national primary drinking 
water regulation for perchlorate pursuant 
to this subsection, in accordance with the 
schedule established by this subparagraph. 
‘‘(ii) PROPOSED REGULATIONS.—Not 
later than January 31, 2006, the Adminis-
trator shall propose a national primary 
drinking water regulation for percholate. 
‘‘(iii) 
FINAL
REGULATIONS.—Not 
later than July 31, 2007, after notice and 
opportunity for public comment, the Ad-
ministrator shall promulgate a national 
primary drinking water regulation for per-
chlorate.’’.
Æ
527 
term ‘modified adjusted gross income’ means the 
adjusted gross income of the taxpayer for the tax-
able year increased by any amount excluded 
from gross income under section 911, 931, or 
933. 
‘‘(c) DEFINITIONS.—For purposes of this section— 
‘‘(1) FIRST-TIME HOMEBUYER.—The term ‘first- 
time homebuyer’ means any individual if such indi-
vidual (and if married, such individual’s spouse) had 
no present ownership interest in a principal residence 
during the 3-year period ending on the date of the 
purchase of the principal residence to which this sec-
tion applies. 
‘‘(2) PRINCIPAL
RESIDENCE.—The term ‘prin-
cipal residence’ has the same meaning as when used 
in section 121. 
‘‘(3) PURCHASE.— 
‘‘(A) IN
GENERAL.—The term ‘purchase’ 
means any acquisition, but only if— 
‘‘(i) the property is not acquired from 
a person related to the person acquiring it, 
and 
‘‘(ii) the basis of the property in the 
hands of the person acquiring it is not de-
termined—
I 
109TH CONGRESS 
1ST SESSION H. R. 1883 
To reduce temporarily the duty on Cyfluthrin (Baythroid). 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 27, 2005 
Mr. CLEAVER introduced the following bill; which was referred to the 
Committee on Ways and Means 
A BILL 
To reduce temporarily the duty on Cyfluthrin (Baythroid). 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. CYFLUTHRIN (BAYTHROID). 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.05.77 
Cyano-(4-fluoro-3- 
phenoxyphenyl)methyl-3- 
(2,2-dichloroethenyl)–2,2- 
dimethylcyclopropanecarbox-
ylate (CAS No. 68359–37– 
5) (provided for in sub-
heading 2926.90.30) ............
3.5% 
No change 
No change 
On or before 
12/31/2008 
’’.
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from 
warehouse for consumption, on or after the 15th day after 
the date of enactment of this Act. 
Æ
(1) in subsection (a), by striking paragraph (5); 
and 
(2) in subsection (f)(1)(A), by striking ‘‘as re-
ported’’. 
(b) AMENDMENTS
TO SECTION 303 AND CON-
FORMING AMENDMENTS.—(1) Section 303 of the Con-
gressional Budget Act of 1974 is amended by striking ‘‘(a) 
IN GENERAL.—’’, by striking ‘‘to become effective’’ in 
paragraph (1), and by striking subsections (b) and (c); 
and 
(2) by striking its section heading and inserting the 
following new section heading: ‘‘CONSIDERATION
OF 
BUDGET-RELATED
LEGISLATION
BEFORE
BUDGET
BE-
COMES LAW’’. 
(c) 
ADDITIONAL
AMENDMENTS.—(1) 
Section 
302(g)(1) of the Congressional Budget Act of 1974 is 
amended by striking ‘‘and, after April 15, section 303’’. 
(2)(A) Section 904(c)(1) of the Congressional Budget 
Act of 1974 is amended by inserting ‘‘303,’’ before 
‘‘305(b)(2),’’. 
(B) Section 904(d)(2) of the Congressional Budget 
Act of 1974 is amended by inserting ‘‘303,’’ before 
‘‘305(b)(2),’’. 
(d) EXPEDITED PROCEDURES UPON VETO OF JOINT 
RESOLUTION ON THE BUDGET.—(1) Title III of the Con-
I 
109TH CONGRESS 
1ST SESSION H. R. 1884 
To suspend temporarily the duty on Beta-cyfluthrin. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 27, 2005 
Mr. CLEAVER introduced the following bill; which was referred to the 
Committee on Ways and Means 
A BILL 
To suspend temporarily the duty on Beta-cyfluthrin. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. BETA-CYFLUTHRIN. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.05.78 
(RS)-α-cyano-4-fluoro-3- 
phenoxybenzyl 
(1RS,3RS;1RS,3SR)–3-(2,2- 
dichlorovinyl)–2,2- 
dimethylcyclopropanecarbox-
ylate (CAS No. 68359–37– 
5) (provided for in sub-
heading 2926.90.30) ............
Free 
No change 
No change 
On or before 
12/31/2008 
’’.
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from 
warehouse for consumption, on or after the 15th day after 
the date of enactment of this Act. 
Æ
I 
109TH CONGRESS 
1ST SESSION H. R. 2140 
To suspend temporarily the duty on Mixtures of N,N-dimethyl-2[3-(4,6- 
dimethoxypyrimidin-2-yl)ureidosulfonyl 
]-4-formylaminobenzamide 
(Foramsulfuron), methyl 4-iodo-2-[3-(4-methoxy-6-methyl-1,3,5-triazin-2- 
yl)ureidosul fonyl]benzoate, sodium salt (Iodosulfuron), and application 
adjuvants. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 5, 2005 
Mr. BERRY introduced the following bill; which was referred to the Committee 
on Ways and Means 
A BILL 
To suspend temporarily the duty on Mixtures of N,N-di-
methyl-2[3-(4,6-dimethoxypyrimidin-2-yl)ureidosulfonyl ]- 
4-formylaminobenzamide (Foramsulfuron), methyl 4- 
iodo-2-[3-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)ureidosul 
fonyl]benzoate, sodium salt (Iodosulfuron), and applica-
tion adjuvants. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
SECTION 
1. 
MIXTURES 
OF 
N,N-DIMETHYL-2[3-(4,6- 
DIMETHOXYPYRIMIDIN-2- 
YL)UREIDOSULFONYL]-4- 
FORMYLAMINOBENZAMIDE 
(FORAMSULFURON), METHYL 4-IODO-2-[3-(4- 
METHOXY-6-METHYL-1,3,5-TRIAZIN-2- 
YL)UREIDOSULFONYL]BENZOATE, 
SODIUM 
SALT (IODOSULFURON), AND APPLICATION 
ADJUVANTS. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.06.72 
Mixtures of N,N-dimethyl- 
2[3-(4,6- 
dimethoxypyrimidin-2- 
yl)ureidosulfonyl]-4- 
formylaminobenzamide 
(Foramsulfuron) (CAS No. 
173159–57–4), methyl 4- 
iodo-2-[3-(4-methoxy-6- 
methyl-1,3,5-triazin-2- 
yl)ureidosulfonyl]benzoate, 
sodium salt (Iodosulfuron) 
(CAS No. 144550–36–7) 
and application adjuvants 
(provided for in subheading 
3808.30.15) .........................
Free 
No change 
No change 
On or before 
12/31/2008 
’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from 
warehouse for consumption, on or after the 15th day after 
the date of the enactment of this Act. 
Æ
section (a)(4)(A) shall extend for up to 90 days (as 
determined by the treating health care professional) 
from the date of the notice described in subsection 
(a)(3)(A). 
(2) INSTITUTIONAL OR INPATIENT CARE.—The 
transitional period under this subsection for a con-
tinuing 
care 
patient 
described 
in 
subsection 
(a)(4)(B) shall extend until the earlier of— 
(A) the expiration of the 90-day period be-
ginning on the date on which the notice under 
subsection (a)(3)(A) is provided; or 
(B) the date of discharge of the patient 
from such care or the termination of the period 
of institutionalization, or, if later, the date of 
completion of reasonable follow-up care. 
(3) SCHEDULED
NON-ELECTIVE
SURGERY.— 
The transitional period under this subsection for a 
continuing care patient described in subsection 
(a)(4)(C) shall extend until the completion of the 
surgery involved and post-surgical follow-up care re-
lating to the surgery and occurring within 90 days 
after the date of the surgery. 
(4) 
PREGNANCY.—The 
transitional 
period 
under this subsection for a continuing care patient 
described in subsection (a)(4)(D) shall extend
through the provision of post-partum care directly 
related to the delivery. 
(5) TERMINAL ILLNESS.—The transitional pe-
riod under this subsection for a continuing care pa-
tient described in subsection (a)(4)(E) shall extend 
for the remainder of the patient’s life for care that 
is directly related to the treatment of the terminal 
illness or its medical manifestations. 
(c) PERMISSIBLE
TERMS
AND
CONDITIONS.—A 
group health plan or health insurance issuer may condi-
tion coverage of continued treatment by a provider under 
this section upon the provider agreeing to the following 
terms and conditions: 
(1) The treating health care provider agrees to 
accept reimbursement from the plan or issuer and 
continuing care patient involved (with respect to 
cost-sharing) at the rates applicable prior to the 
start of the transitional period as payment in full 
(or, in the case described in subsection (a)(2), at the 
rates applicable under the replacement plan or cov-
erage after the date of the termination of the con-
tract with the group health plan or health insurance 
issuer) and not to impose cost-sharing with respect 
to the patient in an amount that would exceed the 
cost-sharing that could have been imposed if the
I 
109TH CONGRESS 
1ST SESSION H. R. 1885 
To suspend temporarily the duty on Deltamethrin. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 27, 2005 
Mr. CLEAVER introduced the following bill; which was referred to the 
Committee on Ways and Means 
A BILL 
To suspend temporarily the duty on Deltamethrin. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. DELTAMETHRIN. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.05.79 
(1R,3R)-cis-3-(2,2- 
dibromovinyl)–2,2- 
dimethylcyclopropanecarbox-
ylic acid, (S)-α-cyano-3- 
phenoxybenzyl ester (CAS 
Nos. 52918–63–5 and 
52820–00–5) (provided for 
in subheading 2926.90.30) ..
Free 
No change 
No change 
On or before 
12/31/2008 
’’.
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from 
warehouse for consumption, on or after the 15th day after 
the date of enactment of this Act. 
Æ
I 
109TH CONGRESS 
1ST SESSION H. R. 2141
To suspend temporarily the duty on 1-Propanone, 2-methyl-1-[4- 
(methylthio)phenyl]-2-(4- morpholinyl)–(9cl). 
IN THE HOUSE OF REPRESENTATIVES 
MAY 5, 2005
Mr. BERRY introduced the following bill; which was referred to the Committee 
on Ways and Means 
A BILL 
To suspend temporarily the duty on 1-Propanone, 2-methyl-
1-[4- (methylthio)phenyl]-2-(4- morpholinyl)–(9cl).
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 
1. 
1-PROPANONE, 
2-METHYL-1-[4- 
(METHYLTHIO)PHENYL]-2-(4- MORPHOLINYL)–
9(CL). 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading:
‘‘
9902.05.53
1-Propanone, 2-methyl-1-[4- 
(methylthio)phenyl]-2-(4- 
morpholinyl)–9(cl) (CAS No. 
718–10–5) (provided for in 
subheading 2934.99.39) ......
Free 
No change 
No change 
On or before 
12/31/2008
’’. 
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from 
warehouse for consumption, on or after the 15th day after 
the date of the enactment of this Act.
Æ
contract referred to in subsection (a)(1) had not 
been terminated. 
(2) The treating health care provider agrees to 
adhere to the quality assurance standards of the 
plan or issuer responsible for payment under para-
graph (1) and to provide to such plan or issuer nec-
essary medical information related to the care pro-
vided. 
(3) The treating health care provider agrees 
otherwise to adhere to such plan’s or issuer’s policies 
and procedures, including procedures regarding re-
ferrals and obtaining prior authorization and pro-
viding services pursuant to a treatment plan (if any) 
approved by the plan or issuer. 
(d) RULES OF CONSTRUCTION.—Nothing in this sec-
tion shall be construed— 
(1) to require the coverage of benefits which 
would not have been covered if the provider involved 
remained a participating provider; or 
(2) with respect to the termination of a con-
tract under subsection (a) to prevent a group health 
plan or health insurance issuer from requiring that 
the health care provider— 
(A) notify participants, beneficiaries, or en-
rollees of their rights under this section; or
(B) provide the plan or issuer with the 
name of each participant, beneficiary, or en-
rollee who the provider believes is a continuing 
care patient. 
(e) DEFINITIONS.—In this section: 
(1) CONTRACT.—The term ‘‘contract’’ includes, 
with respect to a plan or issuer and a treating 
health care provider, a contract between such plan 
or issuer and an organized network of providers that 
includes the treating health care provider, and (in 
the case of such a contract) the contract between the 
treating health care provider and the organized net-
work. 
(2) HEALTH
CARE
PROVIDER.—The term 
‘‘health care provider’’ or ‘‘provider’’ means— 
(A) any individual who is engaged in the 
delivery of health care services in a State and 
who is required by State law or regulation to be 
licensed or certified by the State to engage in 
the delivery of such services in the State; and 
(B) any entity that is engaged in the deliv-
ery of health care services in a State and that, 
if it is required by State law or regulation to be 
licensed or certified by the State to engage in
I 
109TH CONGRESS 
1ST SESSION H. R. 1886 
To suspend temporarily the duty on cyclopropane-1,1-dicarboxylic acid, 
dimethyl ester. 
IN THE HOUSE OF REPRESENTATIVES 
APRIL 27, 2005 
Mr. CLEAVER introduced the following bill; which was referred to the 
Committee on Ways and Means 
A BILL 
To suspend temporarily the duty on cyclopropane-1,1- 
dicarboxylic acid, dimethyl ester. 
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled, 
SECTION 1. CYCLOPROPANE-1,1-DICARBOXYLIC ACID, DI-
METHYL ESTER. 
(a) IN GENERAL.—Subchapter II of chapter 99 of 
the Harmonized Tariff Schedule of the United States is 
amended by inserting in numerical sequence the following 
new heading: 
‘‘ 
9902.05.80 
Cyclopropane-1,1- 
dicarboxylic acid, dimethyl 
ester (CAS No. 6914–71–2) 
(provided for in subheading 
2917.20.00) .........................
Free 
No change 
No change 
On or before 
12/31/2008 
’’.
(b) EFFECTIVE DATE.—The amendment made by 
subsection (a) applies to goods entered, or withdrawn from 
warehouse for consumption, on or after the 15th day after 
the date of enactment of this Act. 
Æ
106TH CONGRESS
2D SESSION
H. CON. RES. 229
CONCURRENT RESOLUTION
Expressing the sense of Congress regarding the
United States Congressional Philharmonic Soci-
ety and its mission of promoting musical excel-
lence throughout the educational system and en-
couraging people of all ages to commit to the love
and expression of musical performance.